OCTREOTID Labatec sol inj 1 mg/5ml flac 5 ml
7680651100019
CH-65110
H01CB02
07.16.2.
Reimbursement limitations:
SANDOSTATIN
Tumeurs du système endocrine gastroentéropancréatique.
Acromégalie qui ne réagit pas ou pas suffisamment à d'autres …
1 / 3
google
Details
- Product number
- 6511001
- CPT
- -
- Packaging group
- 1 x 5 ml
- Unit
- Durchstechflasche(n)
- Composition
- octreotidum 1 mg ut octreotidi acetas, glycinum, mannitolum, phenolum, acidum hydrochloridum, aqua ad iniectabile q.s. ad solutionem pro 5 ml.
Articles (1)
Octreotid Labatec 0.2 mg/ml, Solution pour injection
Solution pour injection
1 x 5 ml
Official Swissmedic V2 data
Additional information from the official database
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
1.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | WIZUS |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | Konservierungsstoff (Conservateur) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 92.05
Specialties list
Yes
Generic
Yes
Reimbursement limitation
SL addition date:
01/07/2014
Authorization holder
Labatec Pharma SA
1217 Meyrin
Authorization information
- Swissmedic authorization number
- 65110
- Drug name
- Octreotid Labatec 0.2 mg/ml, Solution pour injection
- Galenic form
- LSPA
- ATC Code
- H01CB02
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 16/04/2014
- Authorization expiration date
- 31/12/9999
- IT number
- 07.16.2.
- Domain
- Human medicine
Packaging details
- Description (FR)
- OCTREOTID Labatec sol inj 1 mg/5ml flac 5 ml
- Description (DE)
- OCTREOTID Labatec Inj Lös 1 mg/5ml Durchstf 5 ml
- Market launch
- 16/04/2014
- Narcotic (BTM)
- No